The Global Stem Cell Partnering Terms and Agreements 2010-2021 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in stem cell partnering Deal terms analysis Partnering agreement structure Partnering contract documents Top deals by value Most active dealmakers Average deal terms for stem cells
The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.
The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.
The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Stem Cell partnering field; both the leading deal values and most active Stem Cell dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 650 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of Stem Cell dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Stem Cell dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Stem Cell deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Stem Cell dealmaking with a brief summary followed by a comprehensive listing of Stem Cell deals announded by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of Stem Cell partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Stem Cell partnering deals signed and announced since Jan 2010. The chapter is organized by specific Stem Cell technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Stem Cell technologies and products.
Key benefits Global Stem Cell Partnering Terms and Agreements 2010-2021 provides the reader with the following key benefits: In-depth understanding of Stem Cell deal trends since 2010 Access to headline, upfront, milestone and royalty data Detailed access to actual Stem Cell contracts entered into by leading biopharma companies Identify most active Stem Cell dealmakers since 2010 Insight into terms included in a Stem Cell partnering agreement, with real world examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope Global Stem Cell Partnering Terms and Agreements 2010-2021 is intended to provide the reader with an in-depth understanding and access to Stem Cell trends and structure of deals entered into by leading companies worldwide.
Stem Cell Partnering Terms and Agreements includes: Trends in Stem Cell dealmaking in the biopharma industry since 2010 Analysis of Stem Cell deal structure Access to headline, upfront, milestone and royalty data Access to Stem Cell contract documents Leading Stem Cell deals by value since 2010 Most active Stem Cell dealmakers since 2010
In Global Stem Cell Partnering Terms and Agreements 2010-2021, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Stem Cell PartneringTerms and Agreements 2010-2021 report provides comprehensive access to available deals and contract documents for over 650 Stem Cell deals.
Analyzing actual contract agreements allows assessment of the following: • What are the precise rights granted or optioned? • What is actually granted by the agreement to the partner company? • What exclusivity is granted? • What is the payment structure for the deal? • How are sales and payments audited? • What is the deal term? • How are the key terms of the agreement defined? • How are IPRs handled and owned? • Who is responsible for commercialization? • Who is responsible for development, supply, and manufacture? • How is confidentiality and publication managed? • How are disputes to be resolved? • Under what conditions can the deal be terminated? • What happens when there is a change of ownership? • What sublicensing and subcontracting provisions have been agreed? • Which boilerplate clauses does the company insist upon? • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? • Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
This IDC Perspective discusses biopharmaceutical digital technology transfer for manufacturing. Digital technology transfer for biopharma manufacturing will help life science companies bring new drugs to the market more quickly and with higher quality by eliminating electronic document-centric processes associated with replicating recipe,...
The Global Microbiome Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Microbiome partnering deals Disclosed headlines, upfronts, milestones and royalties by...
The global oncology biosimilars market exhibited strong growth during 2015-2020. Cancer is a lifestyle disease that occurs due to the abnormal growth of cells and may result in the formation of a tumor. At present, most of the effective cancer treatments are based on biological drugs, also known as biologics, and include...
The biosimilar market reached a value of US$ 7.7 Billion in 2020. This market is currently being driven by a number of factors such as patent expires of blockbuster biological drugs, lower prices, rising prevalence of chronic diseases, and cost-saving initiatives from governments and third-party payers. Catalyzed by these factors, the market...
Interferon Alpha/Beta Receptor 1 (Cytokine Receptor Class II Member 1 or Cytokine Receptor Family 2 Member 1 or Type I Interferon Receptor 1 or IFNAR1) - Drugs in Development, 2021 Summary Interferon Alpha/Beta Receptor 1 (Cytokine Receptor Class II Member 1 or Cytokine Receptor Family 2 Member 1...
The global cell dissociation market size is projected to reach USD 561 million by 2026 from USD 282 million in 2021, at a CAGR of 14.7% during the forecast period. The growth in this market is attributed to the prevalence of cell based research, the increasing number of pharmaceutical and biotechnology companies. Moreover, the growth opportunities...
The Global Precision Medicine Partnering Terms and Agreements 2014-2021 report provides comprehensive understanding and unprecedented access to the Precision Medicine partnering deals and agreements entered into by the worlds leading healthcare companies. This report provides details of the latest Precision Medicine...
193 pages •
By Global Industry Analysts
• Apr 2021
- Global Biopharmaceutical Bioseparation Systems Market to Reach $12.6 Billion by 2027
- Amid the COVID-19 crisis, the global market for Biopharmaceutical Bioseparation Systems estimated at US$7.1 Billion in the year 2020, is projected to reach a revised size of US$12.6 Billion by 2027, growing at aCAGR...
182 pages •
By Global Industry Analysts
• Apr 2021
- Global Erythropoietin Drugs Market to Reach $19.2 Billion by 2027
- Amid the COVID-19 crisis, the global market for Erythropoietin Drugs estimated at US$11.5 Billion in the year 2020, is projected to reach a revised size of US$19.2 Billion by 2027, growing at a CAGR of 7.5% over the analysis period 2020-2027....
Global Coronavirus Partnering 2014 to 2021 provides the full collection of Coronavirus disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Coronavirus partnering deals Financial deal terms for headline, upfront and royalty by stage of development Coronavirus...
Research And Development
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.